Abernethy to leave FDA in April; plus ICER, Maze, Nuvalent and Andera

FDA Principal Deputy Commissioner Amy Abernethy announced Tuesday that she plans to leave the agency in mid- to late April. Abernethy, who is also serving as acting chief information officer, said on Twitter that she will “spend some time with my family and do some brainstorming, reading & writing.” Prior to joining FDA Abernethy was CMO/CSO and SVP for oncology at Flatiron Health. In a memo to FDA staff, Acting FDA Commissioner Janet Woodcock hailed Abernethy a “relentless advocate for improving the science that informs FDA decision-making.”

The Institute for Clinical and Economic Review appointed Joy Lewis, SVP of health equity strategies at the American Hospital Association, and Chris Jennings, president and founder of Jennings Policy Strategies Inc., as governance board members. ...